Stockreport

Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF The company is moving ahead with Phase 3 plans for IPF-related chronic cough, supported by encouraging trial results and new funding. See our latest analysis for Trevi [Read more]